Description

Simple

Clinical

Overview

Fibrinolysin (also known as bovine plasmin) is a bovine enzyme derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90,000 daltons. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Pharmacology

Indication

Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.

Pharmacodynamic

Information currently not available.

Mechanism of action

Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Almost completely inactivated after 24 hours.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fibrinolysin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(1,2,6,7-3H)Testosterone
(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Fibrinolysin.
(R)-warfarin
The risk or severity of bleeding can be increased when Fibrinolysin is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding can be increased when Fibrinolysin is combined with (S)-Warfarin.
1-Testosterone
1-Testosterone may increase the anticoagulant activities of Fibrinolysin.
18-methyl-19-nortestosterone
18-methyl-19-nortestosterone may increase the anticoagulant activities of Fibrinolysin.
3,5-Diiodotyrosine
3,5-Diiodotyrosine may increase the anticoagulant activities of Fibrinolysin.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Fibrinolysin is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone
4-Hydroxytestosterone may increase the anticoagulant activities of Fibrinolysin.
5beta-dihydrotestosterone
5beta-dihydrotestosterone may increase the anticoagulant activities of Fibrinolysin.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Fibrinolysin.
Abciximab
The risk or severity of bleeding can be increased when Abciximab is combined with Fibrinolysin.
Aceclofenac
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Fibrinolysin.
Acemetacin
The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Fibrinolysin.
Acenocoumarol
The risk or severity of bleeding can be increased when Acenocoumarol is combined with Fibrinolysin.
Acetylsalicylic acid
Acetylsalicylic acid may increase the anticoagulant activities of Fibrinolysin.
Alaproclate
The risk or severity of hemorrhage can be increased when Alaproclate is combined with Fibrinolysin.
Albutrepenonacog alfa
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Fibrinolysin.
Alclofenac
The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Fibrinolysin.
Aldesleukin
The risk or severity of bleeding can be increased when Fibrinolysin is combined with Aldesleukin.
Alemtuzumab
The risk or severity of bleeding can be increased when Fibrinolysin is combined with Alemtuzumab.
1 References
  1. 1 . Birk Y, Khalef S, Jibson MD: Purification and properties of protease F, a bacterial enzyme with chymotrypsin and elastase specificities. Arch Biochem Biophys. 1983 Sep;225(2):451-7.PubMed: 6226244